دورية أكاديمية
Phthalimide-tethered isatins as novel poly(ADP-ribose) polymerase inhibitors: Design, synthesis, biological evaluations, and molecular modeling investigations.
| العنوان: | Phthalimide-tethered isatins as novel poly(ADP-ribose) polymerase inhibitors: Design, synthesis, biological evaluations, and molecular modeling investigations. |
|---|---|
| المؤلفون: | El Hassab MA; Department of Medicinal Chemistry, Faculty of Pharmacy, King Salman International University (KSIU), Ras Sudr, South Sinai, Egypt., El-Hafeez AAA; Cancer Biology Department, Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Cairo, Egypt., Almahli H; Department of Chemistry, University of Cambridge, Cambridge, UK., Elsayed ZM; Scientific Research and Innovation Support Unit, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt., Eldehna WM; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.; School of Biotechnology, Badr University in Cairo, Badr City, Egypt., Hassan GS; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.; Pharmaceutical Chemistry Department, School of Pharmacy, Badr University in Cairo (BUC), Badr City, Egypt., Abou-Seri SM; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt. |
| المصدر: | Archiv der Pharmazie [Arch Pharm (Weinheim)] 2024 Mar; Vol. 357 (3), pp. e2300599. Date of Electronic Publication: 2023 Dec 15. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-VCH Verlag GmbH & Co. KGaA Country of Publication: Germany NLM ID: 0330167 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-4184 (Electronic) Linking ISSN: 03656233 NLM ISO Abbreviation: Arch Pharm (Weinheim) Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005->: Weinheim Germany : Wiley-VCH Verlag GmbH & Co. KGaA Original Publication: Weinheim, Verlag Chemie GmbH. |
| مواضيع طبية MeSH: | Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Isatin*, Male ; Humans ; Structure-Activity Relationship ; Phthalimides/pharmacology ; Cell Line, Tumor |
| مستخلص: | Humanity is currently facing various diseases with significant mortality rates, particularly those associated with malignancies. Numerous enzymes and proteins have been identified as highly promising targets for the treatment of cancer. The poly(ADP-ribose) polymerases (PARPs) family comprises 17 members which are essential in DNA damage repair, allowing the survival of cancer cells. Unlike other PARP family members, PARP-1 and, to a lesser extent, PARP-2 show more than 90% activity in response to DNA damage. PARP-1 levels were shown to be elevated in various tumor cells, including breast, lung, ovarian, and prostate cancer and melanomas. Accordingly, novel series of phthalimide-tethered isatins (6a-n, 10a-e, and 11a-e) were synthesized as potential PARP-1 inhibitors endowed with anticancer activity. All the synthesized molecules were assessed against PARP-1, where compounds 6f and 10d showed nanomolar activities with IC (© 2023 Deutsche Pharmazeutische Gesellschaft.) |
| References: | J. E. Klaunig, Curr. Pharm. Des. 2019, 24(40), 4771. K. Cheung-Ong, G. Giaever, C. Nislow, Chem. Biol. 2013, 20, 648. J. Zhang, Q. Dai, D. Park, X. Deng, Genes 2016, 7(8), 51. R. Huang, P. K. Zhou, Signal Transduct. Target. Ther. 2021, 6(1), 254. P. L. Fischhaber, A. S. Gall, J. A. Duncan, P. B. Hopkins, Cancer Res. 1999, 59, 4363. N. P. Staff, A. Grisold, W. Grisold, A. J. Windebank, Ann. Neurol. 2017, 81(6), 772. K. K. Jain, Front. Oncol. 2018, 8, 419. M. R. Radu, A. Prădatu, F. Duică, R. Micu, S. M. Creţoiu, N. Suciu, D. Creţoiu, V. N. Varlas, V. E. Rădoi, Biomedicines 2021, 9(6), 693. H. Chen, H. Liu, G. Qing, Signal Transduct. Target. Ther. 2018, 3(1), 5. E. E. Alemasova, O. I. Lavrik, Nucleic Acids Res. 2019, 47(8), 3811. Z. Gu, W. Pan, W. Chen, Q. Lian, Q. Wu, Z. Lv, X. Cheng, X. Ge, BMC Plant Biol. 2019, 19, 364. X. Lin, W. Jiang, J. Rudolph, B. J. Lee, K. Luger, S. Zha, Nucleic Acids Res. 2022, 50(7), 3958. G. K. Herrmann, Y. W. Yin, Biomolecules 2023, 13(8), 1195. Y. Zhao, L. X. Zhang, T. Jiang, J. Long, Z. Y. Ma, A. P. Lu, Y. Cheng, D. S. Cao, Eur. J. Med. Chem. 2020, 203, 112570. L. Luo, K. Keyomarsi, Expert Opin. Invest. Drugs 2022, 31(6), 607. L. Wang, C. Liang, F. Li, D. Guan, X. Wu, X. Fu, A. Lu, G. Zhang, Int. J. Mol. Sci. 2017, 18(10), 2111. E. Sachdev, R. Tabatabai, V. Roy, B. J. Rimel, M. M. Mita, Target. Oncol. 2019, 14, 657. M. Y. Keung, Y. Wu, F. Badar, J. V. Vadgama, J. Clin. Med. 2020, 9(4), 940. W. M. Eldehna, M. A. El Hassab, M. F. Abo-Ashour, T. Al-Warhi, M. M. Elaasser, N. A. Safwat, H. Suliman, M. F. Ahmed, S. T. Al-Rashood, H. A. Abdel-Aziz, R. El-Haggar, Bioorg. Chem. 2021, 110, 104748. T. Al-Warhi, M. F. Abo-Ashour, H. Almahli, O. J. Alotaibi, M. M. Al-Sanea, G. H. Al-Ansary, H. Y. Ahmed, M. M. Elaasser, W. M. Eldehna, H. A. Abdel-Aziz, J. Enzyme Inhib. Med. Chem. 2020, 35(1), 1300. M. S. Taghour, H. Elkady, W. M. Eldehna, N. M. El-Deeb, A. M. Kenawy, E. B. Elkaeed, A. A. Alsfouk, M. S. Alesawy, A. M. Metwaly, I. H. Eissa, J. Enzyme Inhib. Med. Chem. 2022, 37(1), 1903. M. El-Naggar, W. Eldehna, H. Almahli, A. Elgez, M. Fares, M. Elaasser, H. Abdel-Aziz, Molecules 2018, 23(6), 1420. W. M. Eldehna, R. I. Al-Wabli, M. S. Almutairi, A. B. Keeton, G. A. Piazza, H. A. Abdel-Aziz, M. I. Attia, J. Enzyme Inhib. Med. Chem. 2018, 33(1), 867. W. M. Eldehna, S. T. Al-Rashood, T. Al-Warhi, R. O. Eskandrani, A. Alharbi, A. M. El Kerdawy, J. Enzyme Inhib. Med. Chem. 2021, 36(no. 1), 271. W. Eldehna, M. Fares, H. Ibrahim, M. Alsherbiny, M. Aly, H. Ghabbour, H. Abdel-Aziz, Molecules 2016, 21(6), 762. https://doi.org/10.3390/molecules21060762. W. M. Eldehna, R. Salem, Z. M. Elsayed, T. Al-Warhi, H. R. Knany, R. R. Ayyad, T. B. Traiki, M. H. Abdulla, R. Ahmad, H. A. Abdel-Aziz, R. El-Haggar, J. Enzyme Inhib. Med. Chem. 2021, 36(1), 1423. B. Gyawali, D. A. Goldstein, JAMA Oncol.2018, 4(5), 623. P. R. Sankar, A. B. Sailu, M. M. Eswarudu, M. N. Satya, P. Sreeja, P. Roja, S. Rijwana, J. Pharm. Sci. Res. 2021, 13(6), 313. W. M. Eldehna, A. M. El Kerdawy, G. H. Al-Ansary, S. T. Al-Rashood, M. M. Ali, A. E. Mahmoud, Eur. J. Med. Chem. 2019, 163, 37. W. M. Eldehna, A. Altoukhy, H. Mahrous, H. A. Abdel-Aziz, Eur. J. Med. Chem. 2015, 90, 684. G. G. Amare, B. G. Meharie, Y. M. Belayneh, J. Oncol. Pharm. Pract. 2021, 27(3), 673. T. D. Penning, Curr. Opin. Drug Discov. Dev. 2010, 13(5), 577. R. Min, W. Wu, M. Wang, L. Tang, D. Chen, H. Zhao, C. Zhang, Y. Jiang, Molecules 2019, 24(no. 10), 1901. Sichuan University. Phthalimide derivative as well as preparation method and application thereof. CN110028439 A. 2019. https://doi.org/10.1080/13543776.2021.1886275 . Y. M. Syam, M. M. Anwar, S. S. Abd El-Karim, K. M. Elokely, S. H. Abdelwahed, Molecules 2022, 27(15), 4924. P. G. Jain, B. D. Patel, Eur. J. Med. Chem. 2019, 165, 198. A. Chen, Chin. J. Cancer 2011, 30, 463. G. F. Elmasry, E. E. Aly, F. M. Awadallah, S. M. El-Moghazy, Bioorg. Chem. 2019, 87, 655. D. V. Ferraris, J. Med. Chem. 2010, 53(12), 4561. E. Eldhose, B. Gowramma, M. Mohammed, R. Kalirajan, L. Kaviarasan, Res. J. Pharm. Technol. 2019, 12(6), 3098. G. D. Zhu, J. Gong, V. B. Gandhi, X. Liu, Y. Shi, E. F. Johnson, C. K. Donawho, P. A. Ellis, J. J. Bouska, D. J. Osterling, A. M. Olson, C. Park, Y. Luo, A. Shoemaker, V. L. Giranda, T. D. Penning, Bioorg. Med. Chem. 2012, 20, 4635. L. Wang, F. Liu, N. Jiang, W. Zhou, X. Zhou, Z. Zheng, Molecules 2016, 21, 772. G. Zhang, Z. Tang, S. Fan, C. Li, Y. Li, W. Liu, X. Long, W. Zhang, Y. Zhang, Z. Li, Z. Wang, D. Chen, G. Ouyang, J. Enzyme Inhib. Med. Chem. 2023, 38(1), 2163393. J. John Francis Xaiver, K. Krishnasamy, C. Sankar, Med. Chem. Res. 2012, 21, 345. https://doi.org/10.1007/s00044-010-9528-6. B. Shamshad, R. Jamal, U. Ashiq, M. Mahrooof-Tahir, Z. Shaikh, S. Sultan, K. Khan, Med. Chem. 2015, 11(8), 798. A. El-Faham, W. N. Hozzein, M. A. M. Wadaan, S. N. Khattab, H. A. Ghabbour, H. K. Fun, M. R. Siddiqui, J. Chem. 2015, 2015, 1. P. Czeleń, A. Skotnicka, B. Szefler, Int. J. Mol. Sci. 2022, 23(14), 8046. https://doi.org/10.3390/ijms23148046. K. K. Chinchilli, A. Angeli, P. S. Thacker, L. N. Korra, R. Biswas, M. Arifuddin, C. T. Supuran, Metabolites 2020, 10(5), 200. https://doi.org/10.3390/metabo10050200. F. Zhao, C. Liu, Y. Sun, Q. Li, J. Zhao, Z. Li, B. Zhang, C. Lu, Q. Li, S. Qiao, Y. S. Zhao, Org. Electron. 2019, 74, 276. A. Hernández-Santoyo, A. Y. Tenorio-Barajas, V. Altuzar, H. Vivanco-Cid, C. Mendoza-Barrera, Protein Eng. Technol. Appl. 2013, 63. M. A. El Hassab, T. M. Ibrahim, A. A. Shoun, S. T. Al-Rashood, H. M. Alkahtani, A. Alharbi, R. O. Eskandrani, W. M. Eldehna, RSC Adv. 2021, 11(26), 16026. T. E. H. Ogden, J. C. Yang, M. Schimpl, L. E. Easton, E. Underwood, P. B. Rawlins, M. M. McCauley, M. F. Langelier, J. M. Pascal, K. J. Embrey, D. Neuhaus, Nucleic Acids Res. 2021, 49(4), 2266. M. A. El Hassab, W. M. Eldehna, S. T. Al-Rashood, A. Alharbi, R. O. Eskandrani, H. M. Alkahtani, E. B. Elkaeed, S. M. Abou-Seri, J. Enzyme Inhib. Med. Chem. 2022, 37(1), 563. W. Humphrey, A. Dalke, K. Schulten, J. Mol. Graphics 1996, 14, 33. H. Yu, Y. Zhao, C. Guo, Y. Gan, H. Huang, Biochim. Biophys. Acta - Proteins Proteom. 2015, 1854(1), 65. M. S. Valdés-Tresanco, M. E. Valdés-Tresanco, P. A. Valiente, E. Moreno, J. Chem. Theory Comput. 2021, 17(10), 6281. O. Trott, A. J. Olson, J. Comput. Chem. 2010, 31(2), 455. M. A. El Hassab, T. M. Ibrahim, S. T. Al-Rashood, A. Alharbi, R. O. Eskandrani, W. M. Eldehna, J. Enzyme Inhib. Med. Chem. 2021, 36(1), 727. M. J. Abraham, T. Murtola, R. Schulz, S. Páll, J. C. Smith, B. Hess, E. Lindahl, SoftwareX 2015, 1-2, 19. A. W. Sousa da Silva, W. F. Vranken, BMC Res. Notes 2012, 5, 367. https://doi.org/10.1186/1756-0500-5-367. W. M. Eldehna, M. A. El Hassab, Z. M. Elsayed, T. Al-Warhi, H. Elkady, M. F. Abo-Ashour, M. A. S. Abourehab, I. H. Eissa, H. A. Abdel-Aziz, Sci. Rep. 2022, 12, 12821. https://doi.org/10.1038/s41598-022-15050-8. |
| معلومات مُعتمدة: | None |
| فهرسة مساهمة: | Keywords: antitumor agents; biological activities; breast cancer; indolin-2-one; molecular dynamics |
| المشرفين على المادة: | 0 (Poly(ADP-ribose) Polymerase Inhibitors) 82X95S7M06 (Isatin) 1J6PQ7YI80 (phthalimide) 0 (Phthalimides) |
| تواريخ الأحداث: | Date Created: 20231215 Date Completed: 20240304 Latest Revision: 20240304 |
| رمز التحديث: | 20240304 |
| DOI: | 10.1002/ardp.202300599 |
| PMID: | 38100160 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1521-4184 |
|---|---|
| DOI: | 10.1002/ardp.202300599 |